Publications
Scientific evidence behind the ImmunoEngine platform — peer-reviewed papers, technology papers, and whitepapers about neoantigen discovery, immunogenicity prediction, and cancer immunotherapy.
Scientific papers
Peer-reviewed publications co-authored by myNEO scientists in leading journals.
Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy
Saviuk et al. - Nature Immunology, 2026
Peer-reviewed publication investigating the immunogenic potential of ferroptosis-based dendritic cell vaccines for glioma immunotherapy.
DOI: 10.1038/s41467-026-72737-6
Accelerating neoantigen discovery: a high throughput approach to immunogenic target identification
Pfitzer et al. – Vaccines, 2025
Peer-reviewed publication presenting a high-throughput approach to immunogenic neoantigen target identification for personalized cancer vaccines.
Methods behind neoantigen prediction for personalized anticancer vaccines
Godazandeh et al. – Methods in Cell Biology, 2023
Review of computational methods for neoantigen prediction in personalized anticancer vaccine development, covering MHC binding, presentation, and immunogenicity.
DOI: 10.1016/bs.mcb.2023.05.002
Neoantigen-directed therapeutics in the clinic: where are we?
Lybaert et al. – Trends in Cancer, 2023
Review article on the clinical landscape of neoantigen-directed therapeutics including personalized cancer vaccines and adoptive cell therapies.
DOI: 10.1016/j.trecan.2023.02.004
Challenges in neoantigen-directed therapeutics
Lybaert et al. – Cancer Cell, 2022
Analysis of key challenges in neoantigen-directed cancer therapeutics including target identification accuracy, immune evasion, and clinical translation.
DOI: 10.1016/j.ccell.2022.10.013
neoMS: attention-based prediction of MHC-I epitope presentation
Mill et al. – BioRxiv, 2022
Publication on neoMS: an attention-based deep learning algorithm for best-in-class HLA-agnostic MHC-I epitope presentation prediction.
DOI: 10.1101/2022.05.13.491845
A synthetic DNA template for fast manufacturing of versatile single epitope mRNA
De Mey et al. – Molecular Therapy Nucleic Acids, 2022
Research on a synthetic DNA template assembly process for cost- and time-efficient manufacturing of single neoepitope mRNA vaccines with validated T-cell activation.
DOI: 10.1016/j.omtn.2022.08.021
Technology papers
In-depth technical documentation for individual myNEO solutions.
myADA – Next-generation Anti-Drug Antibody risk prediction
Technology paper on myADA: a next-generation, in-silico tool for accurate Anti-Drug Antibody (ADA) risk prediction powered by advanced MHC class II epitope immunogenicity modeling.
myEPITOPE – Next-generation immunogenicity prediction
Technology paper on myEPITOPE: high-precision immunogenicity prediction for CD8+ T-cell responses using the proprietary neoIM algorithm, enabling de-risked preclinical validation.
myCONSTRUCT – Next-generation string-of-beads construct optimization for multi-epitope immunotherapeutics
Technology paper on myCONSTRUCT: rational multi-epitope construct design that minimizes junctional epitopes and preserves therapeutic focus through predictive engineering.
mySELF – Next-generation immunogenicity prediction for autoimmune disease and immune tolerance
Technology paper on mySELF: immunogenic and tolerogenic self-antigen prediction for autoimmune disease research, powered by best-in-class neoIM-derived algorithms.
Whitepapers
Thought-leadership documents on key topics in cancer immunotherapy and neoantigen biology.
Case study: revolutionizing cancer treatment in personalized vaccine development
Case study demonstrating how myNEO's ImmunoEngine neoantigen discovery pipeline supports personalized cancer vaccine development through comprehensive neoantigen discovery.
Camyotopes: a novel class of tumor targets
Whitepaper introducing camyotopes — dark genome-derived antigens representing a novel class of tumor targets for next-generation immunotherapies.
There is more to the genome: increasing the range of actionable high-confidence neoantigen discovery by WGS
Whitepaper on whole genome sequencing for neoantigen discovery, demonstrating the value of looking beyond exome-only approaches.
Simulated sequencing data for tool benchmarking and performance assessment
Whitepaper on using simulated sequencing data for benchmarking neoantigen prediction tools and assessing algorithm performance.
Optimal neoantigen prediction and selection – where's the sweet spot?
Whitepaper exploring the balance between sensitivity and specificity in neoantigen prediction for personalized cancer immunotherapy.
Liquid biopsies in personalized medicine – future and pitfalls
Whitepaper on liquid biopsy applications in personalized medicine, including circulating tumor DNA analysis for cancer monitoring.
Beyond SNVs and indels for neoantigen prediction in cold tumors
Whitepaper on extending neoantigen prediction beyond traditional SNVs and indels to address immunologically cold tumors.
Transposable elements in cancer
Whitepaper on the role of transposable elements in cancer immunology and their potential as therapeutic targets.
How the gut microbiome affects cancer immunotherapy
Whitepaper exploring the impact of gut microbiome composition on cancer immunotherapy efficacy and patient outcomes.
The promise of personalized cancer vaccination
Whitepaper on the promise and current state of personalized cancer vaccination approaches using neoantigen-based strategies.
Is immunotherapy the holy grail in the fight against cancer?
Whitepaper examining the potential and limitations of immunotherapy as a cancer treatment paradigm.
Immunosurveillance and the importance of CD4 T-cells in cancer
Whitepaper on the critical role of CD4 T-cells in cancer immunosurveillance and the implications for immunotherapy design.
What is neoMS?
neoMS is myNEO's HLA-agnostic MHC epitope presentation prediction algorithm. It uses a transformer-based attention architecture trained on 386,647 epitopes to model the antigen-processing pathway, including proteasomal cleavage, TAP transport, MHC binding, and presentation.
What is neoIM?
neoIM is myNEO's immunogenicity prediction algorithm. It predicts whether an epitope will activate T cells. In published retrospective analyses, neoIM achieved up to 30% higher precision than existing predictors and identified up to 50% more clinically actionable neoantigens.
What types of publications does myNEO provide?
myNEO publishes peer-reviewed scientific papers, technology papers describing individual solutions, and whitepapers covering neoantigen discovery, immunogenicity prediction, cancer vaccines, camyotopes, and computational immunology.
Talk to our team
Discuss how this research can support target discovery, immunogenicity prediction, or product design.